Outlook and valuation: We expect the company to post a healthy loan book CAGR of 23% over FY2017-20E, which is likely to translate in earnings CAGR of 26%, over the same period. At the current level, the stock is valued at 1.7x FY2020E ABV. We maintain BUY on the stock, and retain our target price of `720. ..